Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival

被引:57
作者
Zeljic, Katarina [1 ,2 ]
Supic, Gordana [1 ]
Radak, Marina Stamenkovic [2 ]
Jovic, Nebojsa [3 ]
Kozomara, Ruzica [3 ]
Magic, Zvonko [1 ]
机构
[1] Mil Med Acad, Inst Med Res, Belgrade 11002, Serbia
[2] Univ Belgrade, Fac Biol, Belgrade 11000, Serbia
[3] Mil Med Acad, Clin Maxillofacial Surg, Belgrade 11002, Serbia
关键词
CYP24A1; CYP27B1; genetic polymorphisms; oral cancer risk; survival; vitamin D receptor; BREAST-CANCER; PROSTATE-CANCER; HEAD; VARIANTS; SUSCEPTIBILITY; CARCINOMA; COLON;
D O I
10.1111/j.1600-0714.2012.01164.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
BACKGROUND: Genetic polymorphisms of vitamin D receptor gene (VDR) and genes involved in vitamin D metabolism pathway, CYP27B1 and CYP24B1, may affect individual susceptibility to oral squamous cell carcinoma. The purpose of this study was to evaluate the associations between VDR, CYP27B1 and CYP24A1 gene polymorphisms with oral cancer risk and survival. METHODS: Study cohort consisted of 110 patients with oral cancer and 122 healthy controls. The genotypes of the analysed genes were determined by PCRRFLP or real-time PCR method. RESULTS: The significant decrease of oral cancer risk was observed in individuals with heterozygote genotype of CYP24A1 gene (rs2296241) (odds ratio 0.281, P = 0.000) in comparison with wild type. Patients with VDR FokI ff wild type genotype had significantly worse overall survival (P = 0.012, log rank) compared with heterozygous and mutated genotype combined. A stratified analysis by the lymph node involvement and tumour stage showed that ff is associated with poor survival in groups with and without lymph node involvement (P = 0.025, P = 0.040, respectively) and in stage III tumours (P = 0.026). Multivariate Coxs regression analysis revealed that VDR FokI could be considered an independent prognostic factor. CONCLUSION: Our findings indicate that CYP24A1 gene polymorphism might have an influence on the susceptibility to oral cancer. VDR FokI polymorphism was associated with worse survival and could be considered as an independent prognostic marker. J Oral Pathol Med (2012) 41: 779-787
引用
收藏
页码:779 / 787
页数:9
相关论文
共 42 条
[1]  
Abo-Hanger E, 2008, J APPL SCI RES, V4, P929
[2]   The role of vitamin D in breast cancer [J].
Aung, Tu Tu ;
Chandana, Sreenivasa R. ;
D'Silva, Karl J. ;
Dimitrov, Nikolay V. .
ONCOLOGY REVIEWS, 2009, 3 (01) :19-25
[3]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[4]  
Bektas-Kayhan K, 2010, IN VIVO, V24, P755
[5]  
Bid Hemant K, 2005, Asian Pac J Cancer Prev, V6, P147
[6]   Vitamin D and cancer [J].
Bouillon, Roger ;
Eelen, Guy ;
Verlinden, Lieve ;
Mathieu, Chantal ;
Carmeliet, Geert ;
Verstuyf, Annemieke .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 102 (1-5) :156-162
[7]   Vitamin D receptor genotypes/haplotypes and prostate cancer risk [J].
Cicek, Mine S. ;
Liu, Xin ;
Schumacher, Fredrick R. ;
Casey, Graham ;
Witte, John S. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (12) :2549-2552
[8]   Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1,25-dihydroxyvitamin D3 [J].
Colin, EM ;
Weel, AEAM ;
Uitterlinden, AG ;
Buurman, CJ ;
Birkenhäger, JC ;
Pols, HAP ;
van Leeuwen, JPTM ;
van Leeuwen, .
CLINICAL ENDOCRINOLOGY, 2000, 52 (02) :211-216
[9]   Vitamin D signalling pathways in cancer: potential for anticancer therapeutics [J].
Deeb, Kristin K. ;
Trump, Donald L. ;
Johnson, Candace S. .
NATURE REVIEWS CANCER, 2007, 7 (09) :684-700
[10]   Vitamin D Related Genes, CYP24A1 and CYP27B1, and Colon Cancer Risk [J].
Dong, Linda M. ;
Ulrich, Cornelia M. ;
Hsu, Li ;
Duggan, David J. ;
Benitez, Debbie S. ;
White, Emily ;
Slattery, Martha L. ;
Farin, Fred M. ;
Makar, Karen W. ;
Carlson, Christopher S. ;
Caan, Bette J. ;
Potter, John D. ;
Peters, Ulrike .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (09) :2540-2548